San Diego-based Orexigen Therapeutics, a biopharmaceutical firm developing treatments for central nervous system disorders, has set the pricing range for the company's IPO. The firm said in a filing with the SEC last night that it will offer 6,000,000 shares of its common stock between $11.00 and $13.00 per share. The company is looking to trade as OREX on the Nasdaq Global Market. The IPO is being underwritten by Merrill Lynch & Co., JPMorgan, JMP Securities, and Leerink Swann & Company. The firm is venture backed by Domain Associates, Kleiner Perkins Caufield and Byers, Montreux Equity Partners, Morgenthaler Ventures, MPM Capital, Scale Venture Partners, Sofinnova Ventures, and Wasatch Advisors.
Top NewsTuesday, April 10, 2007
Orexigen Sets IPO Pricing Range